Autopsy report · NCT05488626
Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer
Cause of deathSlow enrollment
“Shifting patterns of care for the target population.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Na
- Sponsor
- Varian, a Siemens Healthineers Company
- Sponsor type
- Industry
- Conditions
- Stage III Non-small Cell Lung Cancer
- Interventions
- Adaptive Radiotherapy; Non-Adaptive Radiotherapy; Chemotherapy; Immunotherapy
- Participants
- 0
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
“Due to the changes of standard of care and the slow recruitment of participants.” - RAPA-501-Allo Therapy of COVID-19-ARDS
“Change in eligible patient population” - Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
“Lack of enrollment and changing landscape of standard of care.” - Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
“evolving standard of care and difficulties of enrolling participants” - Pembrolizumab and Olaparib in Cervical Cancer Patients
“Poor accrual related to change in standard of care treatment for this population.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.